



Branded Products Business Division

Hao Pan, Senior Vice President



Disclaimer


This presentation contains forward-looking statements which involve risks and uncertainty factors. These statements are not based on historical facts but relate to the Company's future activities and performance. They include statements about future strategies and anticipated benefits of these strategies.

These statements are subject to risks and uncertainties. Actual results may differ substantially from those stated in any forward-looking statement. This is due to a number of factors, including the possibility that Orion may decide not to implement these strategies and the possibility that the anticipated benefits of implemented strategies are not achieved. Orion assumes no obligation to update or revise any information included in this presentation.


All the figures in this presentation have been rounded, which is why the total sums of individual figures may differ from the total sums shown.

This presentation is for investor use only. Not to be used for other purposes.

Overview of Branded Products Business Division



Sales split in Q1'23



Build on the current portfolio in Europe and Asia-Pacific



¹ Entacapone brands: Stalevo®, Comtess® & Comtan®

Building blocks for growth – Branded Products

Maximise the value of
the current product
portfolio

Easyhaler®
Entacapone¹
HRT² range

Build on the current
product portfolio


Respiratory
Parkinson's disease
Other CNS³
Women's Health

How


Internal R&D
Amneal collaboration
In-licensing
Geographic expansion
M&As

¹ Entacapone brands: Stalevo®, Comtess® & Comtan®, ² Hormone Replacement Therapies (=Divina® series) ³ Central Nervous System

Orion as a leading company in Parkinson's Disease




Entacapone remains an important product for Orion even 10 years after loss of exclusivity




Fermion's share of global entacapone production (Orion estimate)

- 1 Orion-developed generic levodopa-carbidopa product in a launch phase in Europe
- 2 Parkinson's Disease (PD) products with generic substances under development



Easyhaler® continues to be a great story for Orion



Green transition increases demand for DPIs...



Green transition – probably the greatest megatrend impacting our generation

Healthcare systems are doing their bit – initiatives to reduce the use of MDIs (metered-dose inhalers)...

...and guiding to use DPIs like Easyhaler® (dry-powder inhalers)

- **Global Initiative For Asthma 2023¹**


"Optimal inhaler selection – safest and best for patients and for the planet"

- **Delivering A 'Net Zero' NHS, UK 2022²**

"The NHS Long Term Plan set targets to deliver significant and accelerated reductions in the total emissions from the NHS by moving to lower carbon inhalers, such as dry powder inhalers (DPIs)"

- **Climate-conscious prescription of inhaled medications DEGAM, GERMANY 2022³**

Potential methods to reduce carbon consumption in kg CO₂



* Annual impact

Source: Climate-conscious prescription of inhaled medications DEGAM, GERMANY 09.2022

...and creates growth opportunities for Easyhaler®

- Easyhaler® is a dry-powder inhaler (DPI)
- A broad portfolio of products particularly in segments, which are dominated by MDIs and where there are limited alternative DPIs available
- Increased demand for mono products (ie. with one active pharmaceutical ingredient) should open growth opportunities also for combination products
- Increased presence and awareness required
- Easyhaler® product portfolio has potential to exceed EUR 200 million in annual sales



Key success factors



Take care of
supply chains



Implementation of
green initiatives in
Europe



Production
efficiency



Ensure portfolio
expansion through
in-licensing and R&D




Managing
pricing pressure



Adapt to possible
changes in
regulation

Key takeaways

1. Green transition creates further growth opportunities for Easyhaler®
2. Orion remains a leading company in Parkinson's Disease
3. Current portfolio a good platform to build on new business in respiratory, Parkinson's Disease, other CNS and Women's Health



The ORION logo is displayed in white, bold, uppercase letters within a blue circular graphic element in the top-left corner of the image. The background of the image shows a close-up of a laboratory instrument, likely a multi-well plate reader or a similar analytical device. It features a metal frame with a row of blue, conical sample wells. Above the wells, there are several black cables with blue connectors plugged into a metal block. The overall scene is brightly lit, with a clean, professional appearance.